Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316602 | 0.88 | CREBBP (0.40) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL29471215 | 0.88 | CREBBP (0.40) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL24317122 | 0.88 | CTSD (0.40) | CYP3A4MAOA | |
| SCHEMBL24316865 | 0.87 | GABRA1 (0.35) | MAOA | |
| SCHEMBL26549131 | 0.87 | MAOA (0.34) | PDE10AMAOA | |
| SCHEMBL24316863 | 0.87 | CFTR (0.36) | PDE10AMAOAFGFR1FGFR4 | |
| SCHEMBL24317119 | 0.83 | POLB (0.34) | PDE10A | |
| SCHEMBL24317120 | 0.83 | FGFR1 (0.32) | PDE10AMAOAFGFR1FGFR2FGFR4 | |
| SCHEMBL24316774 | 0.83 | PRKDC (0.36) | MAOA | |
| SCHEMBL24316890 | 0.82 | BRD4 (0.33) | EGFRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | EGFR 1994/4885PDE10A 2684/4885CYP3A4 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.